Mission
ExoCan is the first exosome based oncology company in India developing innovative cancer diagnosis and therapeutics technologies. ExoCan aims to translate the clinical potential of these tiny vesicles for better management of cancers by employing cross-disciplinary approaches at the forefront of exosomes research. We are building up a broad range of biofluids ( e.g. urine, saliva, blood) based oncoplatforms for cancer detection, drug delivery, and R&D purposes.
Our Skill
Cancer Diagnosis Technologies
Drug Discovery
Exosome Technologies
Drug Repurposing
Management
Dr Aman Sharma
Director and Founder
Aman is a PhD in biotechnology. He has more than 8 years of research experience in biotechnology. Dr Aman developed next generation, novel 3-dimenational tumor models for reinventing personalized therapy and high content drug screenings during his PhD tenure at National Centre for Cell Science (NCCS), Pune, India. Dr Aman has insight for technology identification and value creation in life science based enterprises. He is activelyinvolved in bringing the interdisciplinary skill sets to the development of novel oncotechnologiesfor a complete paradigm shift in cancer diagnosis, therapeutics approaches. He is responsible for overall company management and overlooks company’s R&D.
Anil Sharma
Director
Anil Sharma is a trained legal expert and a Law Graduate. With more than 15 years of experience in service sector and legal affairs he is a seasoned subject matter expert. Anil’s expertise is in team building strategies, and managerial level leadership to promote company’s associations with outside organizations including cancer hospitals. Anil is also apt in understanding the market place behavior, and product market fit approach. He also takes care of strategic expansion of the company beyond its current geography.
A step ahead in precision medicine
With the development of patented high throughput exosome platforms, EXOCAN is committed to leverage the enormous potential of these tiny vesicles for managing cancers clinically. Now, a complete molecular snapshot of a cancer is possible just by taking biofluid samples-urine, saliva, blood/serum and analysing their exosome contents for providing clinically relevant information non-invasively in cancer patients. ExoCan offers high throughput exosome assay systems which can be used for various purposes.
- Cancer geno/phenotyping for personalized medicine
- Research & Development based low sample volume, high throughput exosome assay systems
- Drug delivery & resistance study by combining a patient derived primary 3-D culture models, and a well-format based patented exosome technology
Patents
ExoCan is actively pursuing development of scientific knowledge driven technology platforms. We have a pool of process, and product technology platform development in pipeline for patenting. Our technology IPs relies in the following sectors:
- Novel methods of faster, specific exosomes enrichment
- Portable exosomes technology devices for real time therapy monitoring
- Exosome therapeutics platforms
- 3-Dimentional tumor models
- Drug discovery, high-content screening platforms
Investors
ExoCan is funded by a seed grant from Biotechnology Research Assistance Council (BIRAC), New Delhi, India. ExoCan also received other Govt grants in association with our Academic collaborators in India
Partnering
ExoCan is an innovation driven Oncology company.We have active tie-ups with esteemed Academic Institutions across India. ExoCan believes in fostering the innovation through bridging across cross-disciplinary expertise for building cutting edge technologies in oncology.
If you are interested in associating with ExoCan, please contact us: contact@exocanhealthcare.com